- Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) received an award for up to $63.2 million from the Biomedical Advanced Research and Development Authority (BARDA).
- The award provides three years to support preclinical, manufacturing, and nonclinical safety studies, along with development and regulatory support for Arcturus’ self-amplifying mRNA vaccine platform technology for rapid pandemic influenza response through Phase 1 studies.
- Also see: Arcturus’ COVID-19 Booster Shows Durability Against Omicron Variants.
- The company says its self-amplifying mRNA vaccine has been administered to over 10,000 individuals globally, demonstrating favorable safety, strong immunogenicity, and protection against SARS-COV-2 infection.
- Price Action: ARCT shares are down 2.68% at $13.66 on the last check Thursday.
F-star Therapeutics Enters Exclusive Licensing Agreement With AstraZeneca For Novel STING Inhibitors; F-Star Eligible For Upfront And Near-Term Payments Of $12M And Milestones Of Over $300M
F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to
